Ndeapi basa rePARP inhibitor rinogona kuita murope rehapa remucheche? Miti mishonga inozivikanwa sePARP inhibitors yakadzidzwa munguva pfupi yekurapa kenza yepamu. Chii chinonzi mishonga iyi yemishonga, uye chii chingava iyo yekupedzisira inobata mukutarisira kwevanhu vane kenza yemazamu?
Nezve PARP uye DNA Repair
PARP inotsanangurwa ne poly (ADP-ribose) polymerase.
PARP ipuroteni ine mabasa akawanda mumasero emagetsi, kunyanya muDNA kugadzirisa uye programmed cell cell death (apoptosis). Masero anopa utano anogona kushandisa PARP kuzvigadzirisa pachavo uye kurarama hupenyu hwavo hunoenderana. Asi kenza mashandisi anogonawo kushandisa PARP kugadzirisa DNA kukanganisa, nokudaro kuwedzera kukura kwavo kusingadzorwi. Izvozvo zvinodhaka zvinogona kusagadzikana pakurapa. Kune zvikamu zvakasiyana zvakasiyana zvePARP, uye mumwe nomumwe ane basa rake pachake mumabasa mukati memasero.
PARP Inhibitors Uye Breast Cancer Treatment
A PARP inhibitor imishonga inovhara mapuroteni ePAR kubva pakuita mabasa avo mukugadzirisa masero emukenza akaora. Chemotherapy uye mushonga wewadhiroyo kuburikidza nokuputsa DNA yemasero kuitira kuti vasazobereka. Dzimwe mhando dzekenza masero dzinoshandisa maPerzy enzymes kuti dzigadzirise DNA yavo kukuvara uye dzidzoke kubva pakurwa kwekenza mishonga. Mitezo yakawanda yemakiriniki ari kuitwa kuti aone kana PARP inhibitors, yakabatana nemamwe marapirwo emishonga, inogona kudzivirira puroteni yePAR kubva pamasero ekenza yakaora.
Migumisiro Pamakero eCcercer
Kana PARP inhibitor inowanikwa chemotherapy yekenza yepazamu, vatsvakurudzi vanotarisira kuti masero emukenza anoramba mishonga yekurwisa mishonga ichava pangozi yekuparara kweDNA kukuvara. Mune zvimwe zviitiko, PARP inhibitor inogona kushandiswa yoga , pane kuti ibatane ne chemo uye miviri.
Kunyange zviri nani nyaya ndeyokuti PARP inhibitors haisi kuonekwa kuti inokanganisa masero, asina-kanzura. Izvozvo zvinoreva kusava nemigumisiro yechirwere kune varwere uye nekukurumidza kupora kubva kumishonga.
Tariro yeHereditary Breast Cancers
PARP inhibitor inogona kubatsira zvikuru kune varwere vane kenza yepamuviri. Vanhu vane BRCA1 uye BRCA2 kuchinja kwemashoko vari mumwero wakanyanya wekudzidzira kenza yebonde. Utano hwakanaka BRCA mazai anogadzira mapuroteni anogona kukonesa kuora kwemaitiro ( anonzi tumor suppressor genes ), asi mutengesi weGCA weGCA hauna simba pakuita mapuroteni aya anorwa nekenza masero. PARP inhibitors inogona kushandisa kushaya simba kunoitwa nekenza masero ane BRCA yakashandurwa. Imwe inogona kushandiswa yePARP inhibitor inogona kunge iri kudzivirira kenza yepabonde . Zvichida PARP inhibitors ichava inodzivirira kurapwa kwevakadzi vane ngozi uye yaizoita kuti prophylactic mastectomies isapera.
Kukurudzira Nhau dzeTatu-Dzakaipa Mazamu Makondombera
Zvimwe zviongorori zvezvipatara zvePARP inhibitors zvakawana zvimwe zvipatara zvinobatsira kubva kuwedzera PARP inhibitor kune dzimwe nzira dzokurapa kwechirwere chetachiona chetatu chisingaiti chepabonde . Mune zvidzidzo izvi, PARP inhibitors yakanyatsorambidzwa. Panguva ino chete chirongwa chinotenderwa kuongororwa chetachiona chemasamende chemastrase isvacizumab, asi ichi chinodhaka hachina ruzivo rwakanyanya kune vanhu vane kenza yepabonde katatu-isina.
Zvimwe Zvishandiswa zvePARP Inhibitors
Zvinodhaka zvakagadzirwa nePARP inhibitors zviri kuedzwa pamhando dzakasiyana-siyana dzekenza: mazamu uye ovarian, uterine, uropi, uye pancreatic. Muna 2015, PARP inhibitor yakagamuchirwa kuitira kurapwa kwemamwe makondombera ovari.
Zvichida kukosha kwePARP Inhibitors
Kuwedzerwa kwePARP inhibitors kune ikozvino arsenal yezvombo zvinorwisa kenza yemazamu inotaridzika kwazvo. PARP inhibitors inowedzera kubudirira kwemakemikrasi kurwisana nehutsinye uye hutatu-zvisina hutano hwekenza, zvichida pasina kuwedzera yakawanda migumisiro yakaipa. Iyi mishonga inoratidzika kuvandudza hupenyu hwehupenyu pamwe nekuwedzera kupona kwevarwere.
Kurwisana nekenza yemazamu pamwero weDNA yayo inotaridzika sezvenje remangwana.
> Sources:
> Boerner, J. et al. Zviratidzo zvePurotini zveDNA Dambudziko rekugadzirisa mapuroteni rinotarisana nekupindurwa neTopoisomerase uye PARP Inhibitor MuTrans-negative Breast Cancer. PLOS One . 2015. 10 (3: e0119614.
> Comen, E., uye M. Robson. Poly (ADP-ribose) Polymerase Inhibitors muTatu-negative Breast Cancer. Cancer Journal . 2010. 16 (1): 48-52.
> Dizdar, O., Arslan, C., naK. Altundaq. Kufambira mberi muPAR Inhibitors yeKurapwa kweBear Cancer. Expert Opinion in Pharmacotherapy . 2015. 16 (18): 2751-8.
> Garber, J., uye L. Livraghi. PARP Inhibitors mumutungamiri weChechi yeKana: Current Data uye Future Future Expected. BMC Medicine . 2015. 13: 188.
> Hiller, D., uye Q. Chu. Mamiriro Emazuva Ano ePol (ADP-ribose) Polymerase Inhibitors seRavel Therapeutic Agents for Triple-Negative Breast Cancer. International Journal of Breast Cancer . 2012. 2012: 829315.
> Lee, J. et al. Chidzidzo I / Ib Yokudzidza yeOlaparib neCarboplatin muBrCA1 kana BRCA2 Mutation-inobatanidza Breast kana Ovarian Cancer Ne Biomarker Analyzes. Zvinyorwa zveNational Cancer Institute . 2014. 106 (6): dgo089.
> O'Shaughnessy, J. et al. Iniparib Plus Chemotherapy muMetastatic Triple-negative Breast Cancer. The New England Journal of Medicine . 2011. 364 (3): 205-14.
> O'Shaughnessy, J. et al. Nyaya yeCliniki Oncology . 2014. 32 (34): 3840-7.
> O'Sullivan, C., Chen, A., uye S. Kummar. Kununura paZvimbiso: Poly ADP Ribose Polymerase Inhibition inotarirwa AnticancerTtherapy. Ikozvino Maonero muOnology . 2015. 27 (6): 475-81.
> Rios, J., uye S. Puhalla. PARP Inhibitors mu Breast Cancer: BRCA uye Beyond. Oncology (Williston park) . 2011. 25 (11): 1014-25.
> van der Noll, R. et al. Nguva Yekuchengetedzwa Kwekuchengetedzwa uye Kuzvidzivirira Kwebasa Basa reOlaparib Monotherapy Mushure mekubatana neCarboplatin nePaclitaxel muVachipatara NeBreat Breast, Ovarian kana Fallopian Tube kenza. British Journal of Cancer . 2015. 113 (3): 396-402.